Verona shares slide on half-year figures but chief executive optimistic on COPD trial data

9 September 2015

us on the US

Shares in UK-based biotech company Verona (LSE: VRP) fell as the company announced its first-half 2015 financial figures, but the news came simultaneously with positive trial data.

Speaking to The Pharma Letter on the day of the release of new clinical data and half-year financials, Verona’s chief executive Jan-Anders Karlsson said: “Admittedly there’s not a lot of new clinical data, but the data we’ve had out today is very encouraging and we’re excited about that. Taken together, it really demonstrates that the compound in the new formulation is exciting.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK